Status:
COMPLETED
The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines
Lead Sponsor:
Medy-Tox
Conditions:
Glabellar Frown Lines
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
To Confirm the non-inferiority of CUNOX® to BOTOX® in the glabellar line improvement of moderate to severe glabellar lines.
Eligibility Criteria
Inclusion
- Men and women aged between 18 and 65
- Subjects attaining ≥ grade 2 (moderate) in the investigator's rating of the severity of glabellar lines at maximum forced frown
- Subjects who voluntarily sign the informed consent
Exclusion
- Subjects with allergy or hypersensitivity to the investigational drugs or their components
- Subjects who are participating in other clinical trials or have participated in clinical trials 30 days before screening
- Subjects who are not eligible for this study at the discretion of the investigator
Key Trial Info
Start Date :
December 13 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 3 2019
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT03837561
Start Date
December 13 2018
End Date
June 3 2019
Last Update
July 29 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Medical Center Capital-Health
Moscow, Russia